Citadel Advisors’s T2 Biosystems, Inc TTOO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-10
Closed -$221 15520
2023
Q3
$221 Buy
+10
New +$261 ﹤0.01% 14125
2022
Q4
Sell
-39
Closed -$22K 15628
2022
Q3
$22K Sell
39
-20
-34% -$13.2K ﹤0.01% 12042
2022
Q2
$48K Sell
59
-12
-17% -$17.8K ﹤0.01% 11967
2022
Q1
$185K Buy
71
+13
+22% +$27.6K ﹤0.01% 11634
2021
Q4
$149K Buy
58
+31
+115% +$108K ﹤0.01% 12271
2021
Q3
$123K Sell
27
-10
-27% -$50.3K ﹤0.01% 12618
2021
Q2
$221K Sell
37
-17
-31% -$110K ﹤0.01% 11947
2021
Q1
$434K Buy
+54
New +$572K ﹤0.01% 10004
2020
Q4
Sell
-15
Closed -$91.8K 11675
2020
Q3
$104K Sell
15
-25
-63% -$185K ﹤0.01% 9253
2020
Q2
$253K Sell
40
-9
-18% -$38.2K ﹤0.01% 8195
2020
Q1
$158K Buy
49
+40
+444% +$166K ﹤0.01% 8248
2019
Q4
$52K Buy
9
+6
+200% +$56.7K ﹤0.01% 8746
2019
Q3
$38K Sell
3
-4
-57% -$32.1K ﹤0.01% 8785
2019
Q2
$62K Buy
+7
New +$82K ﹤0.01% 8667
2019
Q1
Sell
-8
Closed -$136K 10024
2018
Q4
$119K Buy
8
+1
+14% +$23.5K ﹤0.01% 8174
2018
Q3
$277K Buy
7
+3
+75% +$98.8K ﹤0.01% 7703
2018
Q2
$141K Buy
+4
New +$152K ﹤0.01% 8102
2016
Q1
Sell
-5
Closed -$289K 8218
2015
Q4
$289K Buy
+5
New +$270K ﹤0.01% 5264

Other funds holding TTOO

Citadel Advisors's TTOO Position: Q4 2023 in Review

Citadel Advisors sold out of T2 Biosystems, Inc (TTOO) in Q4 2023, closing a stake of 10 shares — an estimated $221 sold.

Citadel Advisors first reported a position in TTOO in Q4 2015 and held it in 18 quarters. The position peaked at $434K in Q1 2021. 21 funds tracked by Wall St. Rank hold TTOO as of Q4 2023.

  • Citadel Advisors reported no remaining T2 Biosystems, Inc position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 10 T2 Biosystems, Inc shares in Q4 2023, an estimated $221.
  • Citadel Advisors first reported a position in T2 Biosystems, Inc in Q4 2015 and held it in 18 quarters.
  • Citadel Advisors's T2 Biosystems, Inc position peaked at $434K in Q1 2021.
  • 21 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.